ImpediMed has developed products that use a technology called bioimpedance spectroscopy, which tests for lymphedema, a condition which can occur after cancer treatment, causes swelling and can lead to lifelong complications. It is a must have for the 960,000 or so cancer patients each year in the in the US. The fact that the diagnosis is not invasive at a time when the patient is extremely vulnerable to any procedure is a big positive.

ImpediMed seems to be one of those rare biotechs that is are able to get to market relatively quickly because of the nature of that technology, but still managed to retain a proprietary edge, which is currently unchallenged. The fact that the diagnosis is not invasive at a time when the patient is extremely vulnerable to an invasive procedure is a winning edge.

**12m forecast